Alnylam Says Estimates of Damages in Tekmira Suit Could Reach $1.5B | GenomeWeb

Alnylam Pharmaceuticals this week disclosed that a jury trial for its trade secret litigation with Tekmira Pharmaceuticals is expected to begin Nov. 14.

In the disclosure, which was made concurrent with the Alnylam's release of its third-quarter financial results, the RNAi drug shop noted that its 2012 financial guidance of roughly $280 million in year-end cash, cash equivalents, and marketable securities does not include the impact of payments that could be made in connection with the resolution of the litigation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.